Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 21 Mar 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA: Annual Report 2023 | 20103010 Biotechnology | Annual financial and audit Reports |
| 09 Mar 2024 11:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trades by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 23:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trades by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 08:13 CET |
ULTIMOVACS | Ultimovacs ASA – Mandatory trade notification and disclosure of holding | 20103010 Biotechnology | Major shareholding notifications |
| 07 Mar 2024 23:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insiders | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Mar 2024 16:37 CET |
ULTIMOVACS | Ultimovacs ASA – Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 07 Mar 2024 11:26 CET |
ULTIMOVACS | Ultimovacs ASA – Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 07 Mar 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Mar 2024 18:41 CET |
ULTIMOVACS | Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Feb 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Feb 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Feb 2024 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Feb 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Jan 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 Jan 2024 18:57 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 02 Jan 2024 19:25 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 19 Dec 2023 16:51 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Dec 2023 08:39 CET |
ULTIMOVACS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Dec 2023 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Nov 2023 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Resignation of Aitana Peire from Board of Directors | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Nov 2023 17:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 13 Nov 2023 10:46 CET |
ULTIMOVACS | Ultimovacs ASA: New share capital registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Nov 2023 17:00 CET |
ULTIMOVACS | Ultimovacs ASA: Share capital increase related to exercise of options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Nov 2023 11:18 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Nov 2023 07:00 CET |
ULTIMOVACS | Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Nov 2023 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Nov 2023 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 Oct 2023 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Oct 2023 17:50 CEST |
ULTIMOVACS | Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1 Phase II NIPU Trial in Malignant Mesothelioma | 20103010 Biotechnology | Non-regulatory press releases |
| 23 Oct 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 Cancer Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Oct 2023 18:00 CEST |
ULTIMOVACS | Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Oct 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Oct 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Sep 2023 16:31 CEST |
ULTIMOVACS | Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Aug 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 16 Aug 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Aug 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Jun 2023 16:30 CEST |
ULTIMOVACS | Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2023 15:30 CEST |
ULTIMOVACS | Ultimovacs' Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award's Honorary Prize as an Outstanding Pioneer Against Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Jun 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Jun 2023 14:34 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Jun 2023 12:22 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Jun 2023 19:08 CEST |
ULTIMOVACS | Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 May 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 May 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Apr 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Apr 2023 16:30 CEST |
ULTIMOVACS | Ultimovacs ASA - Share Option Program | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Apr 2023 15:08 CEST |
ULTIMOVACS | Ultimovacs ASA - Annual General Meeting held on 20 April 2023 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Apr 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting | 20103010 Biotechnology | Total number of voting rights and capital |
| 13 Apr 2023 11:31 CEST |
ULTIMOVACS | Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |